	US 11,701,361 B2
	p110-delta inhibitors treat and prevent autoimmunity while sparing the ability to mount an immune response to exogenous immunogens
John Cambier, Denver, CO (US); and Elizabeth Franks, Denver, CO (US)
Assigned to NATIONAL INSTITUTES OF HEALTH (NCH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR), Bethesda, MD (US); and THE REGENTS OF THE UNIVERSITY OF COLORADO, Denver, CO (US)
Appl. No. 16/959,960
Filed by THE REGENTS OF THE UNIVERSITY OF COLORADO, Denver, CO (US)
PCT Filed Jan. 7, 2019, PCT No. PCT/US2019/012532 § 371(c)(1), (2) Date Jul. 2, 2020, PCT Pub. No. WO2019/136373, PCT Pub. Date Jul. 11, 2019.
Claims priority of provisional application 62/614,040, filed on Jan. 5, 2018.
Prior Publication US 2021/0069197 A1, Mar. 11, 2021
Int. Cl. A61K 31/52 (2006.01); A61P 37/02 (2006.01); A61P 3/10 (2006.01)

CPC A61K 31/52 (2013.01) [A61P 3/10 (2018.01); A61P 37/02 (2018.01)]

10 Claims

1. A method of treating or delaying the onset or slowing the progression of an autoimmune disease or disorder in a subject comprising administering a therapeutically effective amount of a phosphoinositide 3-kinase p110-delta (PI3K-p110δ) inhibitor to the subject at a dosage that does not reduce immune response to exogenous immunogens in the subject.